Vanguard Group Inc. Decreases Stock Holdings in Vir Biotechnology, Inc. $VIR

Vanguard Group Inc. lowered its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 3.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,799,381 shares of the company’s stock after selling 427,685 shares during the quarter. Vanguard Group Inc. owned 0.09% of Vir Biotechnology worth $73,084,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in VIR. Raymond James Financial Inc. bought a new stake in shares of Vir Biotechnology in the 2nd quarter worth about $35,000. Federated Hermes Inc. lifted its stake in shares of Vir Biotechnology by 153.8% in the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock valued at $46,000 after purchasing an additional 4,899 shares during the last quarter. Truist Financial Corp purchased a new position in shares of Vir Biotechnology in the 3rd quarter worth approximately $63,000. Daiwa Securities Group Inc. increased its position in shares of Vir Biotechnology by 2,200.6% during the 2nd quarter. Daiwa Securities Group Inc. now owns 12,308 shares of the company’s stock valued at $62,000 after purchasing an additional 11,773 shares during the last quarter. Finally, Los Angeles Capital Management LLC purchased a new stake in Vir Biotechnology during the 2nd quarter valued at $63,000. 65.32% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on VIR. Evercore restated an “outperform” rating and issued a $18.00 price target on shares of Vir Biotechnology in a research report on Tuesday, February 24th. HC Wainwright boosted their price objective on shares of Vir Biotechnology from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday. Leerink Partners reissued an “outperform” rating and issued a $20.00 target price on shares of Vir Biotechnology in a research note on Thursday, February 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a report on Monday, December 22nd. Finally, Morgan Stanley lifted their price target on shares of Vir Biotechnology from $20.00 to $24.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.44.

Vir Biotechnology Stock Performance

Shares of NASDAQ VIR opened at $9.55 on Friday. Vir Biotechnology, Inc. has a fifty-two week low of $4.16 and a fifty-two week high of $10.94. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -3.02 and a beta of 1.65. The business’s 50 day moving average price is $7.34 and its 200-day moving average price is $6.24.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings data on Monday, February 23rd. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.11. The company had revenue of $64.07 million during the quarter, compared to analysts’ expectations of $19.91 million. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.Vir Biotechnology’s revenue was up 417.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.76) EPS. Sell-side analysts predict that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Insider Transactions at Vir Biotechnology

In other news, CEO Backer Marianne De sold 14,762 shares of the company’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $9.53, for a total value of $140,681.86. Following the transaction, the chief executive officer directly owned 1,020,704 shares in the company, valued at approximately $9,727,309.12. This represents a 1.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Vicki L. Sato sold 22,000 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $9.51, for a total transaction of $209,220.00. Following the completion of the transaction, the director directly owned 1,122,391 shares in the company, valued at $10,673,938.41. This represents a 1.92% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 177,546 shares of company stock worth $1,522,174. 16.00% of the stock is currently owned by insiders.

Key Headlines Impacting Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: HC Wainwright materially raised its FY2026 outlook (now -$0.81 vs prior -$2.16) and flipped Q2 2026 to a $0.73 EPS forecast, signaling expectations for much stronger near?term results; the firm retained a “Buy” rating and $20 price target.
• Positive Sentiment: HC Wainwright also nudged several 2026 quarterly estimates higher (Q3/Q4 2026 less negative), which supports the narrative of improving near?term fundamentals and likely helped lift sentiment.
• Positive Sentiment: Management change: Vir named CEO Marianne De Backer as President, expanding her responsibilities — a governance move that can be read as streamlining decision?making and execution. Vir Biotechnology Names CEO Marianne De Backer as President
• Neutral Sentiment: HC Wainwright maintained its Buy rating and $20 target — a supportive endorsement but already priced in by some investors given previous coverage.
• Negative Sentiment: HC Wainwright trimmed longer?term forecasts: FY2027 was lowered (to -$1.99 from -$1.90) and FY2028/FY2029 estimates were reduced (e.g., FY2028 to -$1.65 from -$1.40; FY2029 to -$1.24 from -$1.13), reflecting weaker medium?term profitability expectations that could cap upside if sustained.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical?stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell?based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID?19, HIV, hepatitis B, and tuberculosis.